https://www.socictopen.socict.org/files/original/1001e38928ae1835a74e43f3fe330c4f.pdf 737d5b186d59e9943d6899a683332f80 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Current Status of Treatment Options, Clinical Trials, and Vaccine Development for SARS-CoV-2 Infection Creator An entity primarily responsible for making the resource Yuhong Yang, Ran Jing, Ramarao Vunnam, Adam Karevoll, Srinivas Rao Vunnam Description An account of the resource The severe acute respiratory syndrome virus (SARS-CoV-2), a novel coronavirus first discovered inWuhan, China in December 2019 causes the Coronavirus Disease 19 (COVID-19), which presents with a wide range of clinical symptoms from mild or moderate to severe and critical illnesses. With thecontinuing transmission of the virus worldwide and the rapidly evolving situation globally, the WorldHealth Organization (WHO) declared the COVID-19 outbreak a pandemic in March. Currently, thereis no proven specific treatment for this potentially deadly disease beyond supportive care. However,a massive effort has been put globally into the investigation of medications and other interventionalmeasures to fight COVID-19. Convalescent plasma therapy from recovered patients has recently drawnconsiderable interest. Several alternative medical treatments, although evidence of their efficacy stilllacking, have also gained popularity, especially in countries with such traditions such as India and China.Rapid repurposing of drugs for COVID-19 has revealed a few promising candidate antiviral agents, butfurther research, especially high quality randomized controlled trials, will be needed to prove theirefficacy and safety in the clinical use to treat COVID-19. Vaccine development has been the imperativetask in the battle against SARS-CoV-2. While clinical trials have been launched for several candidatevaccines, research on COVID-19 vaccines is still at an early stage. So far, optimized supportive careremains the best practice against COVID-19. Date A point or period of time associated with an event in the lifecycle of the resource 2020 Subject The topic of the resource vaccine, Supportive care, Clinical trials, SARS-CoV-2, COVID-19 Identifier An unambiguous reference to the resource within a given context DOI: 10.22207/JPAM.14.SPL1.10 Source A related resource from which the described resource is derived Journal of Pure and Applied Microbiology Publisher An entity responsible for making the resource available Journal of Pure and Applied Microbiology Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Microbiology